Getting There: Statin Plus Ezetimibe for Low-Density Lipoprotein Cholesterol Goals

Hurley, Daniel L.; Isley, William L.
May 2005
Mayo Clinic Proceedings;May2005, Vol. 80 Issue 5, p585
Academic Journal
The article presents information on Ezetimibe used for low-density lipoprotein cholesterol. The National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines for lipid lowering can be met at a time when physicians are faced with the burden of increased prevalence of obesity, metabolic syndrome, and diabetes mellitus, all of which would be expected to increase the risk of coronary heart disease (CHD). Ezetimibe is the first drug available for use from the class of cholesterol absorption inhibitors.


Related Articles

  • Fibric acid reduces cardiac events in CHD patients with low HDL.  // Modern Medicine;Dec98, Vol. 66 Issue 12, p45 

    Reports that gemfibrozil is a cost-effective treatment for reducing cardiac events in men with coronary heart disease whose only lipid abnormality is a low level of high-density lipoprotein (HDL). Research conducted by Doctor Hanna Rubins; Explanations from Rubins; Side effect of gemfibrozil.

  • Lipid-Lowering Treatment in Coronary Artery Disease: How Low Should Cholesterol Go? Jones, P.H. // Drugs;May2000, Vol. 59 Issue 5, p1127 

    The randomised clinical trial data, which supports preventing coronary heart disease (CHD) events by lowering low density lipoprotein cholesterol (LDL-C) levels, is substantial, consistent and highly significant. HMG-CoA reductase inhibitors (statins), which are the preferred medications for...

  • Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study. Wenger, N. K.; Lewis, S. J.; Welty, F. K.; Herrington, D. M.; Bittner, V. // Heart;Apr2008, Vol. 94 Issue 4, p434 

    Objective: To examine by secondary analysis of the Treating to New Targets (TNT) study whether the benefits of intensive versus standard levels of lipid lowering are equally applicable to women. Methods: A total of 10 001 patients (1902 women) with stable coronary heart disease (CHD) were...

  • Discovery and refinement of loci associated with lipid levels. Willer, Cristen J; Schmidt, Ellen M; Sengupta, Sebanti; Peloso, Gina M; Gustafsson, Stefan; Kanoni, Stavroula; Ganna, Andrea; Chen, Jin; Buchkovich, Martin L; Mora, Samia; Beckmann, Jacques S; Bragg-Gresham, Jennifer L; Chang, Hsing-Yi; Demirkan, Ayşe; Den Hertog, Heleen M; Do, Ron; Donnelly, Louise A; Ehret, Georg B; Esko, Tõnu; Feitosa, Mary F // Nature Genetics;Nov2013, Vol. 45 Issue 11, p1274 

    Levels of low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides and total cholesterol are heritable, modifiable risk factors for coronary artery disease. To identify new loci and refine known loci influencing these lipids, we examined 188,577...

  • Gemfibrozil Treatment in Patients with Elevated Lipoprotein A: A Pilot Study. Fereshetian, A.G.; Davidson, M.; Haber, H.; Black, D.M. // Clinical Drug Investigation;1998, Vol. 16 Issue 1, p1 

    Objective: This pilot study investigated the efficacy of high-dose gemfibrozil (2400 mg/day) in treating patients with elevated lipoprotein (a) [Lp(a)]. Lp(a) has been shown to be an independent risk factor for the development of coronary heart disease (CHD). Patients: Eleven patients with serum...

  • Pravastatin for patients with average cholesterol levels. Audain, Linz // American Family Physician;2/15/1997, Vol. 55 Issue 3, p942 

    Focuses on a study by F.M. Sacks, et al, published in a 1996 edition of `The New England Journal of Medicine,' which sought to determine the effect of lowering low-density lipoprotein (LDL) cholesterol levels in patients with average cholesterol levels and coronary heart disease. How the study...

  • With CAD patients, assess the risks and lower the lipids. Kraf, Teri J.; Cierpka, Lisa M. // Managed Healthcare;Jan2000, Vol. 10 Issue 1, p43 

    Offers tips for health maintenance organizations on how to manage patients with coronary artery disease (CAD). Disease management program for CAD patients; Lowering of cholesterol.

  • Dietary advice for lowering plasma cholesterol. Haines, A.P.; Sanders, T.A.B. // BMJ: British Medical Journal (International Edition);6/17/89, Vol. 298 Issue 6688, p1594 

    Presents a dietary advice for lowering plasma cholesterol concentration in Great Britain. Reduction in the incidence of coronary heart disease among middle aged men; Importance of a decrease fat intake and energy balance; Need for health professionals to be given dietary guidelines for managing...

  • Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. Muldoon, Matthew F.; Manuck, Stephen B.; Matthews, Karen A. // BMJ: British Medical Journal (International Edition);8/11/90, Vol. 301 Issue 6747, p309 

    Examines the association between reduction of cholesterol concentrations and deaths. Benefits of reducing cholesterol concentrations on health; Evaluation of the total mortality rate; Management and treatment of patients with coronary heart disease.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics